• 5 min read
• Published on 5 August 2025
Listen to article
6:31Hey! We are Nemo.
Nemo, short for Never Miss Out, is a mobile investment platform that delivers curated, data-driven investment ideas to your fingertips. It offers commission-free trading across stocks, ETFs, crypto, and CFDs, along with AI-powered tools, real-time market alerts, and themed stock collections called Nemes.
Download the App
Scan the QR code to download the Nemo app and start investing on Nemo today
Published on 14 September 2026
Read article
Published on 14 September 2026
Read article
Published on 13 September 2026
Read article
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Let’s be honest, most of us have tried our best to forget the last few years. We got the jab, the world reopened, and we all breathed a collective sigh of relief. For many, that was the end of the mRNA story. A useful bit of science that got us out of a tight spot. But to me, that’s like thinking the invention of the microchip was only good for making pocket calculators. The vaccine was merely the opening act, the loud, world-changing proof of concept. The real revolution, the one that could genuinely reshape medicine and create enormous value, is only just beginning.
Think about BioNTech, the German firm that gave us the Pfizer vaccine. They didn’t get into this business to stop us all from catching a nasty flu. Their original, grand ambition was to cure cancer. The pandemic, in a strange twist of fate, handed them a colossal windfall and, more importantly, undeniable proof that their technology works on a global scale. It was the most spectacular, and profitable, clinical trial in human history.
Now, flush with cash and credibility, they are ploughing everything back into their first love. This isn't just a company hedging its bets. It's the logical next step for a technology that is, at its core, an information system for the human body. It can, in theory, teach our cells to build any protein necessary to fight a disease. The speed is what’s truly staggering. While traditional drug development plods along for decades, costing a king's ransom, mRNA therapies can be designed and tweaked on a computer in weeks.
I’ve seen my fair share of biotech fads come and go, promising the earth and delivering a handful of dust. So, what makes this different? Commercial validation. Before 2020, mRNA was a fascinating idea confined to laboratories. The sceptics, and there were many, questioned everything. Could you manufacture it at scale? Would regulators approve it? Would anyone even agree to have this newfangled genetic code injected into them?
Well, billions of doses later, I think we have our answers. The infrastructure is built, the regulatory pathways are mapped out, and the public, by and large, is on board. The technology has been de-risked in a way that almost no other medical breakthrough has. This isn't speculative science fiction anymore. It's a proven, industrial-scale platform. Moderna has followed the same playbook, and even companies like CureVac, which stumbled with their first vaccine, are still in the race, developing mRNA for other diseases. The starting gun has been fired, and the race is well and truly on.
The most profound application, and the one that should have any serious investor paying attention, is cancer. For decades, our main weapon has been chemotherapy, a horribly blunt instrument that poisons the patient in the hope of poisoning the tumour first. Immunotherapy showed promise, but it only works for a select few.
mRNA treatments are a different beast entirely. They aim to turn a patient’s own immune system into a team of highly trained assassins, specifically programmed to hunt and destroy their unique cancer cells. This is the core idea behind the Beyond Vaccines: The mRNA Revolution investment theme, moving from mass prevention to hyper-personalised cures. BioNTech already has treatments for melanoma and breast cancer in trials. If they can pull it off, the impact would be monumental, not just for humanity, but for the investors who backed the right horse.
View the full Basket:Beyond Vaccines: The mRNA Revolution
View the full Basket:Beyond Vaccines: The mRNA Revolution
This article is marketing material and should not be construed as investment advice. No information set out in this article be considered, as advice, recommendation, offer, or a solicitation, to buy or sell any financial product, nor is it financial, investment, or trading advice. Any references to specific financial product or investment strategy are for illustrative / educational purposes only and subject to change without notice. It is the investor’s responsibility to evaluate any prospective investment, assess their own financial situation, and seek independent professional advice. Past performance is not indicative of future results. Please refer to our Risk Disclosure.
Published on 14 September 2026
Read article
Published on 14 September 2026
Read article
Published on 13 September 2026
Read article
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article